Digitalis glycosides are no longer considered first-line treatment for heart failure but are discussed due to their history of use. Digoxin is the prototype agent that comes from foxglove plants and has an oral bioavailability of 70% and half-life of 36 hours. It works by inhibiting sodium-potassium ATPase pumps, increasing intracellular calcium levels and contractility. While it can improve heart failure symptoms, it does not prolong life. Its use for atrial fibrillation aims to slow ventricular rate. Toxicity risks include arrhythmias and are increased by electrolyte imbalances from diuretics. Treatment focuses on correcting deficiencies and using antiarrhythmic drugs or digoxin antibodies.
Digitalis glycosides are no longer considered first-line treatment for heart failure but are discussed due to their history of use. Digoxin is the prototype agent that comes from foxglove plants and has an oral bioavailability of 70% and half-life of 36 hours. It works by inhibiting sodium-potassium ATPase pumps, increasing intracellular calcium levels and contractility. While it can improve heart failure symptoms, it does not prolong life. Its use for atrial fibrillation aims to slow ventricular rate. Toxicity risks include arrhythmias and are increased by electrolyte imbalances from diuretics. Treatment focuses on correcting deficiencies and using antiarrhythmic drugs or digoxin antibodies.
Digitalis glycosides are no longer considered first-line treatment for heart failure but are discussed due to their history of use. Digoxin is the prototype agent that comes from foxglove plants and has an oral bioavailability of 70% and half-life of 36 hours. It works by inhibiting sodium-potassium ATPase pumps, increasing intracellular calcium levels and contractility. While it can improve heart failure symptoms, it does not prolong life. Its use for atrial fibrillation aims to slow ventricular rate. Toxicity risks include arrhythmias and are increased by electrolyte imbalances from diuretics. Treatment focuses on correcting deficiencies and using antiarrhythmic drugs or digoxin antibodies.
Digitalis glycosides are no longer considered first-line drugs in the
treatment of heart failure. However, because they are not discussed elsewhere in this book, we begin our discussion with this group. A. Prototypes and Pharmacokinetics All cardiac glycosides include a steroid nucleus and a lactone ring; most also have one or more sugar residues. The cardiac glycosides are often called digitalis! because several come from the digitalis "fo#glove$ plant. Digoxin is the prototype agent and the only one commonly used in the %nited &tates. A very similar molecule, digito#in, which also comes from the fo#glove, is no longer available in the %nited &tates. Digo#in has an oral bioavailability of '()*+,, and a half-life of -').( h. /limination is by renal e#cretion "about '(,$ and hepatic metabolism ".(,$. . !echanism o" Action 0nhibition of 1a2342 AT5ase of the cell membrane by digitalis is well documented and is considered to be the primary biochemical mechanism of action "6igure 7-)-$. 0nhibition of 1a2342 AT5ase results in a small increase in intracellular sodium. The increased sodium alters the driving force for sodium-calcium e#change by the e#changer, 189, so that less calcium is removed from the cell. The increased intracellular calcium is stored in the sarcoplasmic reticulum and upon release increases contractile force. :ther mechanisms of action for digitalis have been proposed, but they are probably not as important as inhibition of the AT5ase. The conse;uences of 1a2342 AT5ase inhibition are seen in both the mechanical and the electrical function of the heart. Digitalis also modifies autonomic outflow, and this action has effects on the electrical properties of the heart. C. Cardiac E""ects #. !echanica$ e""ects%The increase in contractility evoked by digitalis results in increased ventricular e<ection, decreased end-systolic and end-diastolic si=e, increased cardiac output, and increased renal perfusion. These beneficial effects permit a decrease in the compensatory sympathetic and renal responses previously described. The decrease in sympathetic tone is especially beneficial> reduced heart rate, preload, and afterload permit the heart to function more efficiently "point 8 in 6igure 7-)7 may approach point A as the function curve approaches normal$. &. E$ectrica$ e""ects%/lectrical effects include early cardiac parasympathomimetic responses and later arrhythmogenic actions. They are summari=ed in Table 7-)7. a. Early responses0ncreased 5? interval, caused by the decrease in atrioventricular "A@$ conduction velocity, and flattening of the T wave are common electrocardiogram "/8A$ effects. The effects on the atria and A@ node are largely parasympathetic "mediated by the vagus nerve$ and can be partially blocked by atropine. The increase in the A@ nodal refractory period is particularly important when atrial flutter or fibrillation is present because the refractoriness of the A@ node determines the ventricular rate in these arrhythmias. The effect of digitalis is to slow ventricular rate. &hortened BT, inversion of the T, and &T depression may occur later. b. Toxic responses0ncreased automaticity, caused by intracellular calcium overload, is the most important manifestation of digitalis to#icity. 0ntracellular calcium overload results in delayed afterdepolari=ations, which may evoke e#trasystoles, tachycardia, or fibrillation in any part of the heart. 0n the ventricles, the e#trasystoles are recogni=ed as premature ventricular beats "5@Cs$. Dhen 5@Cs are coupled to normal beats in a 7>7 fashion, the rhythm is called bigeminy "6igure 7-).$. D. C$inica$ 'ses #. Congesti(e heart "ai$)re%Digitalis is the traditional positive inotropic agent used in the treatment of chronic heart failure. However, careful clinical studies indicate that while digitalis may improve functional status "reducing symptoms$, it does not prolong life. :ther agents "diuretics, A8/ inhibitors, vasodilators$ may be e;ually effective and less to#ic, and some of these alternative therapies do prolong life "see later discussion$. Cecause the half-lives of cardiac glycosides are long, the drugs accumulate significantly in the body, and dosing regimens must be carefully designed and monitored &. Atria$ "i*ri$$ation%0n atrial flutter and fibrillation, it is desirable to reduce the conduction velocity or increase the refractory period of the A@ node so that ventricular rate is controlled within a range compatible with efficient filling and e<ection. The parasympathomimetic action of digitalis often accomplishes this therapeutic ob<ective, although high doses may be re;uired. Alternative drugs for rate control include E blockers and calcium channel blockers, but these drugs have negative inotropic effects. E. Interactions Buinidine causes a well-documented reduction in digo#in clearance and can increase the serum digo#in level if digo#in dosage is not ad<usted. &everal other drugs have the same effect "amiodarone, verapamil, others$, but the interactions with these drugs are not clinically significant. Digitalis to#icity, especially arrhythmogenesis, is increased by hypokalemia, hypomagnesemia, and hypercalcemia Foop diuretics and thia=ides, which are always included in the treatment of heart failure, may significantly reduce serum potassium and thus precipitate digitalis to#icity. Digitalis-induced vomiting may deplete serum magnesium and similarly facilitate to#icity. These ion interactions are important in treating digitalis to#icity. +. Digita$is ,oxicity The ma<or signs of digitalis to#icity are arrhythmias, nausea, vomiting, and diarrhea. ?arely, confusion or hallucinations and visual or endocrine aberrations may occur. Arrhythmias are common and dangerous. 8hronic into#ication is an e#tension of the therapeutic effect of the drug and is caused by e#cessive calcium accumulation in cardiac cells "calcium overload$. This overload triggers abnormal automaticity and the arrhythmias noted in Table 7-)7. &evere, acute into#ication caused by suicidal or accidental e#treme overdose results in cardiac depression leading to cardiac arrest rather than tachycardia or fibrillation. Treatment of digitalis to#icity includes several steps, as follows. Correction o" potassi)m or magnesi)m de"iciency 8orrection of potassium deficiency "caused, eg, by diuretic use$ is useful in chronic digitalis into#ication. Gild to#icity may often be managed by omitting 7 or H doses of digitalis and giving oral or parenteral 42 supplements. &evere acute into#ication "as in suicidal overdoses$ usually causes marked hyperkalemia and should not be treated with supplemental potassium. &. Antiarrhythmic dr)gs%Antiarrhythmic drugs may be useful if increased automaticity is prominent and does not respond to normali=ation of serum potassium. Agents that do not severely impair cardiac contractility "eg, lidocaine or phenytoin$ are favored, but drugs such as propranolol have also been used successfully. &evere acute digitalis overdose usually causes marked inhibition of all cardiac pacemakers, and an electronic pacemaker may be re;uired. Antiarrhythmic drugs are dangerous in such patients. -. Digoxin anti*odies%Digo#in antibodies "6ab fragments; Digibind$ are e#tremely effective and should always be used if other therapies appear to be failing. They are effective for poisoning with many cardiac glycosides in addition to digo#in and may save patients who would otherwise die.